Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 1,507 Shares

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 1,507 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total transaction of $72,336.00. Following the transaction, the insider now directly owns 91,163 shares in the company, valued at $4,375,824. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Monday, November 4th, Dennis Cho sold 659 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total transaction of $27,388.04.
• On Wednesday, October 2nd, Dennis Cho sold 3,104 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total transaction of $134,123.84.
• On Friday, September 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The shares were sold at an average price of $46.94, for a total transaction of $10,983.96.

Twist Bioscience Stock Down 6.1 %

Twist Bioscience stock opened at $42.49 on Thursday. Twist Bioscience Co. has a 52 week low of $18.59 and a 52 week high of $60.90. The company’s 50 day moving average price is $43.92 and its two-hundred day moving average price is $45.93. The stock has a market cap of $2.49 billion, a P/E ratio of -11.12 and a beta of 1.78.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently modified their holdings of the company. Signaturefd LLC increased its stake in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the last quarter. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience during the 2nd quarter worth approximately $43,000. Blue Trust Inc. increased its stake in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Twist Bioscience during the 2nd quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TWST. Evercore ISI raised their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Leerink Partners raised their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. Robert W. Baird raised their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Finally, Barclays dropped their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.